Search

Novo Nordisk A-S (Class B)

Abrir

317.9 -1.06

Visão Geral

Variação de preço das ações

24h

Atual

Mín

316.25

Máximo

324.7

Indicadores-chave

By Trading Economics

Rendimento

804M

29B

Vendas

-7.6B

78B

P/E

Médio do Setor

13.098

34.393

EPS

6.53

Rendimento de Dividendos

3.64

Margem de lucro

37.182

Funcionários

77,406

EBITDA

39B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+9.53% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.64%

2.54%

Próxima data de dividendos

19 de ago. de 2025

Próxima data de ex-dividendo

14 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-639B

1.4T

Abertura anterior

318.96

Fecho anterior

317.9

Novo Nordisk A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de ago. de 2025, 06:52 UTC

Ganhos

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 de ago. de 2025, 06:21 UTC

Ganhos

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

8 de ago. de 2025, 05:32 UTC

Conversa de Mercado

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 de ago. de 2025, 11:32 UTC

Ganhos

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 de ago. de 2025, 11:03 UTC

Ganhos

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 de ago. de 2025, 10:41 UTC

Ganhos

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 de ago. de 2025, 20:34 UTC

Ganhos

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 de ago. de 2025, 08:45 UTC

Ganhos

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 de ago. de 2025, 07:19 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 de ago. de 2025, 05:50 UTC

Ganhos

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 de ago. de 2025, 05:48 UTC

Ganhos

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 de ago. de 2025, 05:46 UTC

Ganhos

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 de ago. de 2025, 05:38 UTC

Ganhos

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 de ago. de 2025, 05:37 UTC

Ganhos

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 de ago. de 2025, 05:36 UTC

Ganhos

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 de ago. de 2025, 05:35 UTC

Ganhos

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 de ago. de 2025, 05:34 UTC

Ganhos

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6 de ago. de 2025, 05:31 UTC

Ganhos

Novo Nordisk 2Q Net Pft DKK26.5B

6 de ago. de 2025, 05:31 UTC

Ganhos

Novo Nordisk 2Q Oper Pft DKK33.45B

6 de ago. de 2025, 05:31 UTC

Ganhos

Novo Nordisk 2Q Sales DKK76.86B

5 de ago. de 2025, 21:58 UTC

Ganhos

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 de ago. de 2025, 17:26 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 de ago. de 2025, 15:15 UTC

Ganhos

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5 de ago. de 2025, 10:07 UTC

Conversa de Mercado

Novo Nordisk's Facing Challenging Times -- Market Talk

1 de ago. de 2025, 11:10 UTC

Ações em Alta

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

30 de jul. de 2025, 11:10 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Suffering From Self-Inflicted Wounds -- Market Talk

30 de jul. de 2025, 10:57 UTC

Conversa de Mercado

Novo Nordisk's New CEO Might Need to Change U.S. Strategy -- Market Talk

30 de jul. de 2025, 10:48 UTC

Conversa de Mercado
Ganhos

Novo Nordisk's New CEO Faces Issues With No Easy Fix -- Market Talk

30 de jul. de 2025, 10:42 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Stock Markets Beware Summer Scares. What -2-

30 de jul. de 2025, 10:42 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Stock Markets Beware Summer Scares. What Microsoft Must Learn From Novo's $75 Billion Crash. -- Barrons.com

Novo Nordisk A-S (Class B) Previsão

Preço-alvo

By TipRanks

9.53% parte superior

Previsão para 12 meses

Média 1,162.73 DKK  9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Novo Nordisk A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

7

Comprar

2

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.